Evidence map›Paper›PMID 34743204›Full record

ReviewCell death and differentiation2022

The integrated stress response in ischemic diseases.

Guangyu Zhang, Xiaoding Wang, Beverly A Rothermel, Sergio Lavandero, Zhao V Wang

Abstract readReview
In one paragraph

Review in Cell death and differentiation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Critical illness expands a transcriptionally distinct hypometabolic CD8bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. ISR Modulators in Neurological Diseases.Current neuropharmacology · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Frontiers in pharmacology · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guangyu ZhangDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA.ORCID http://orcid.org/0000-0001-8145-6701
Xiaoding WangDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA.ORCID http://orcid.org/0000-0003-2333-2270
Beverly A RothermelDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA.ORCID http://orcid.org/0000-0001-9037-6703
Sergio LavanderoDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA. slavander@uchile.cl.ORCID http://orcid.org/0000-0003-4258-1483
Zhao V WangDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA. zhao.wang@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-9904-9538

Funding

Training CoreP50HD087351 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI BASSEL-DUBY, RHONDA, IANNACCONE, SUSAN T · 2020 to 2024
$8.0M
Training CoreU54HD087351 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI OLSON, ERIC N · 2015 to 2019
$7.8M
Role of the Xbp1s/GFAT1 axis in pathological cardiac remodellingR01HL137723 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, ZHAO · 2017 to 2025
$4.3M
Elevated mitochondrial fusion and function in Down syndrome - Revision - 2R01HD101006 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI ROTHERMEL, BEVERLY A · 2019 to 2022
$2.2M
Calcineurin Regulates Cardiomyocyte Cell Cycle Through Meis1 and Hoxb13R01HL147276 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SADEK, HESHAM · 2019 to 2022
$1.6M
NHLBI NIH HHS R01 HL137723NHLBI NIH HHS R01 HL147276NICHD NIH HHS P50 HD087351NICHD NIH HHS R01 HD101006NICHD NIH HHS U54 HD087351
6 · The paper itself

Abstract

Ischemic disease is among the deadliest and most disabling illnesses. Prominent examples include myocardial infarction and stroke. Most, if not all, underlying pathological changes, including oxidative stress, inflammation, and nutrient deprivation, are potent inducers of the integrated stress response (ISR). Four upstream kinases are involved in ISR signaling that sense a myriad of input stress signals and converge on the phosphorylation of serine 51 of eukaryotic translation initiation factor 2α (eIF2α). As a result, translation initiation is halted, creating a window of opportunity for the cell to repair itself and restore homeostasis. A growing number of studies show strong induction of the ISR in ischemic disease. Genetic and pharmacological evidence suggests that the ISR plays critical roles in disease initiation and progression. Here, we review the basic regulation of the ISR, particularly in response to ischemia, and summarize recent findings relevant to the actions of the ISR in ischemic disease. We then discuss therapeutic opportunities by modulating the ISR to treat ischemic heart disease, brain ischemia, ischemic liver disease, and ischemic kidney disease. Finally, we propose that the ISR represents a promising therapeutic target for alleviating symptoms of ischemic disease and improving clinical outcomes.

Indexed as

Eukaryotic Initiation Factor-2Stress, PhysiologicalHomeostasisHumansIschemiaPhosphorylationEukaryotic Initiation Factor-2

Identifiers

PMID34743204
PMCPMC8990009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.